Metagenomi, Inc. Common Stock MGX · Stock Open Metagenomi, Inc. Common Stock in new tab
Analyst price targets
Recent rating changes, newest first
Metagenomi, Inc. Common Stock Analysis (MGX)
Is Metagenomi, Inc. Common Stock a good investment? Metagenomi, Inc. Common Stock (MGX) is currently trading at 0.7901 USD. Market analysts have a consensus price target of 7.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: Metagenomi, Inc. Common Stock is expected to release its next earnings report on Nov. 10, 2026. The market consensus estimate for Forward EPS is -1.84.
Investor FAQ
Does Metagenomi, Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Metagenomi, Inc. Common Stock?
Metagenomi, Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 10, 2026. The company currently has a trailing EPS of -2.49.
Company Profile
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Community Discussion